A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

MP0274是一种新型DARPin疗法，靶向人表皮生长因子受体2信号通路，可使转移性人表皮生长因子受体2阳性乳腺癌患者在接受曲妥珠单抗和帕妥珠单抗治疗后出现持续性肿瘤消退。